Harrow In Sharp Focus: This Fast-Growing Pharma Stock Just Got Cheaper

Healthcare investing isn't always about blockbuster drugs – sometimes the best opportunities hide in profitable niches.

In this episode, we sit down with Finimize analyst Russell Burns to dig into Harrow, an ophthalmology pharma company whose stock has dropped 30% in recent weeks despite a still-strong growth outlook.

With shares up 400% over five years – dwarfing the S&P 500 – Russell explains why this pullback might be the entry point investors have been waiting for.

Try Finimize Pro